Artificial Intelligence In Pharmaceutical Formulation Development: From Quality By Design (Qbd) To Autonomous Drug Design

Engineering notes

Recent advances in machine learning, deep learning, generative artificial intelligence, digital twins, autonomous laboratories, and explainable artificial intelligence have significantly expanded the scope of pharmaceutical formulation development beyond the principles of conventional Quality by Design.

Chinese explanation / 中文解读

中文解读待补充：本站会优先为端到端自动驾驶、BEV感知、3D目标检测、轨迹预测、路径规划、LiDAR感知等高价值论文补充中文说明。

Original abstract

Artificial intelligence has emerged as one of the most transformative technologies in pharmaceutical sciences, fundamentally changing the paradigm of drug discovery, formulation development, manufacturing, and quality assurance. Conventional pharmaceutical formulation development primarily relies on empirical experimentation and trial based optimization, which are often time consuming, labor intensive, and resource demanding. The increasing complexity of modern drug molecules, particularly poorly water soluble compounds, biologics, and personalized medicines, has highlighted the limitations of traditional formulation strategies and created a need for more intelligent and predictive development approaches. The integration of artificial intelligence with pharmaceutical sciences has enabled the development of data driven models capable of predicting critical formulation attributes, optimizing manufacturing processes, improving product quality, and accelerating regulatory decision making. Recent advances in machine learning, deep learning, generative artificial intelligence, digital twins, autonomous laboratories, and explainable artificial intelligence have significantly expanded the scope of pharmaceutical formulation development beyond the principles of conventional Quality by Design. Artificial intelligence assisted Quality by Design enables predictive risk assessment, intelligent experimental design, real time process optimization, and continuous quality monitoring throughout the product life cycle. Moreover, emerging technologies such as robotic experimentation, self driving laboratories, and autonomous drug design platforms have the potential to revolutionize pharmaceutical research by reducing development timelines and improving formulation success rates. This review comprehensively discusses the evolution of artificial intelligence in pharmaceutical formulation development, beginning with the principles of Quality by Design and extending toward autonomous drug design. The review also highlights current applications, regulatory perspectives, technological challenges, future opportunities, and research gaps associated with artificial intelligence implementation in pharmaceutical sciences. Collectively, artificial intelligence is expected to become a central component of future pharmaceutical research, enabling more efficient, robust, and personalized formulation development.

Links and sources

Comments